For the quarter ending 2026-03-31, VNRX made $985,076 in revenue. -$6,569,250 in net income. Net profit margin of -666.88%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 985,076 | 447,034 | 627,277 | 406,688 |
| Research and development | 2,852,251 | 2,467,741 | 2,285,907 | 2,720,207 |
| General and administrative | 2,629,826 | 1,795,672 | 2,483,793 | 2,940,754 |
| Sales and marketing | 851,851 | 1,001,675 | 958,567 | 1,043,534 |
| Total operating expenses | 6,333,928 | 5,265,088 | 5,728,267 | 6,704,495 |
| Operating loss | -5,348,852 | -4,818,054 | -5,100,990 | -6,297,807 |
| Interest expense | - | 168,367 | 143,800 | 123,356 |
| Grant income | 120,531 | 86,774 | 232,184 | 75,991 |
| Gain /( loss) on disposal of fixed assets | - | 1,334* | 0 | 330 |
| Interest income | 16 | 122 | 160 | 160 |
| Interest expense | 125,842 | - | - | - |
| Amortization of debt discount | 450,134 | 374,744.5* | 729,630 | 325,305 |
| Gain on change in fair value of warrant liability | 13,416 | 91,792 | 27,842 | -62,764 |
| Loss on change in fair value of derivative liability | 98,642 | -1,121,697.5* | 304,443 | 418,681 |
| Loss on extinguishment of debt | -1,011,334 | - | - | - |
| Total other income (expenses) | -1,354,705 | -1,484,787 | -308,801 | -16,263 |
| Net loss | -6,703,557 | -6,302,841 | -5,409,791 | -6,314,070 |
| Net loss attributable to non-controlling interest | -38,783 | -329,692 | - | 29,992 |
| Net loss attributable to volitionrx stockholders | -6,664,774 | -6,632,533* | - | -6,284,078 |
| Foreign currency translation adjustments | 134,307 | 149,770* | 22,348 | -575,996 |
| Net comprehensive loss | -6,569,250 | -6,482,763 | -5,387,443 | -6,890,066 |
| Diluted EPS | -0.97 | - | -0.05 | -0.06 |
| Diluted Average Shares | 6,882,744 | 119,925,345 | 108,213,068 | 102,654,095 |
VOLITIONRX LTD (VNRX)
VOLITIONRX LTD (VNRX)